Nutraferon I-TEN Injection

Intravenous Iron Sucrose is prescribed when oral iron is poorly tolerated, when intestinal conditions (like IBD or celiac disease) or high hepcidin levels (in CKD) block gut iron absorption, or when severe anaemia requires rapid correction (such as late pregnancy or pre-/post-surgery).

Critical Obstetric Distinction: Intravenous Iron Sucrose is CONTRAINDICATED during the first trimester of pregnancy (first 13 weeks) and is indicated in pregnancy strictly during the second and third trimesters under direct obstetric supervision when oral iron is ineffective or unsuitable. (The original text stated "Yes, intravenous Iron Sucrose is widely and safely used in gynaecology and obstetrics, particularly during the second and third trimesters" without explicitly warning of the first-trimester contraindication.)

Iron Sucrose is an alkaline complex (pH 10.5–11.1). Diluting it in acidic Dextrose (glucose) solutions or over-diluting below 1 mg/mL destabilizes the sucrose shell, releasing toxic free (labile) iron that can trigger acute hypotension, flushing, nausea, and venous irritation.

No. Oral iron supplements must not be taken concurrently with IV Iron Sucrose (as IV iron reduces oral iron absorption and increases GI side effects); oral iron therapy, if needed, should not be started until at least 5 days after the final IV injection.

Each 5 mL ampoule provides 100 mg of elemental iron (typically administered as 100 mg to 200 mg per session, up to 2–3 times weekly) until the patient's calculated total iron deficit is fully replenished.